MedTrace Logo

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-09-16

No results posted yet for this study

Summary

This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active AS.

Conditions

  • Spondylitis, Ankylosing

Interventions

DRUG

Ixekizumab

Administered SC

DRUG

Placebo

Administered SC

DRUG

Adalimumab

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-04-30
Completion
2018-04-30

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • Mexico
  • Netherlands
  • Poland
  • Russia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01870284 on ClinicalTrials.gov